Skip to main content
. 2015 Jun 10;6(26):22666–22679. doi: 10.18632/oncotarget.4433

Figure 4. Expression of the p53 protein and its negative regulator MDM2 after simultaneous and sequential combination therapy in the p53 wild type cell line A549.

Figure 4

A. p53 protein levels after treatment B. MDM2 protein levels after treatment; β-actin was used as an internal standard. C. MDM2 mRNA levels after sequential treatment. D. MDM2 mRNA levels after simultaneous treatment. (*p < 0.05: significant difference compared to 0 μM CDDP; **p < 0.05: significant difference compared to 2 μM CDDP).